LobbyingEndeavor Biomedicines lobbying by quarter
Endeavor Biomedicines's latest lobbying report covers Q2 2026, at $51K. The four quarters Q4 2025–Q3 2026 total $153K. Its first report covers Q1 2025; the issues it reports most are Health Issues.
Endeavor Biomedicines
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $153K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q1 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q1 2025 | $8,500 | 1 |
| Q2 2025 | $51K | 1 |
| Q3 2025 | $51K | 1 |
| Q4 2025 | $51K | 1 |
| Q1 2026 | $51K | 1 |
| Q2 2026 | $51K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$263.5K · 6 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES6 reports
- SENATE6 reports
- Food & Drug Administration (FDA)4 reports
Firms it paid
| Firm | ||
|---|---|---|
| Aviva Strategies | $263.5K | 6 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/17for Q2 | Aviva Strategies | $51K |
| 04/15for Q1 | Aviva Strategies | $51K |
| 01/15for Q4 2025 | Aviva Strategies | $51K |
| 25/10/15for Q3 2025 | Aviva Strategies | $51K |
| 25/07/16for Q2 2025 | Aviva Strategies | $51K |
| 25/05/06for Q1 2025 | Aviva Strategies | $8,500 |
| 25/04/25for Q2 2025 | Aviva Strategies | Under $5,000 |